Atom Investors’s Vir Biotechnology VIR Stock Holding History

Atom Investors’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-33,200	Closed	-$190K	–	818
2025 Q3	$190K	Buy	+33,200	New	+$170K	0.01%	516
2024 Q2	–	Sell	-13,336	Closed	-$135K	–	682
2024 Q1	$135K	Buy	+13,336	New	+$136K	0.02%	505

Other funds holding VIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GSK plc London $599M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Atom Investors's VIR Position: Q4 2025 in Review

Atom Investors sold out of Vir Biotechnology (VIR) in Q4 2025, closing a stake of 33,200 shares — an estimated $190K sold.

Atom Investors first reported a position in VIR in Q1 2024 and held it in 2 quarters. The position peaked at $190K in Q3 2025. 218 funds tracked by Wall St. Rank hold VIR as of Q4 2025.

Atom Investors reported no remaining Vir Biotechnology position as of Q4 2025 after selling out during the quarter.
Atom Investors sold 33,200 Vir Biotechnology shares in Q4 2025, an estimated $190K.
Atom Investors first reported a position in Vir Biotechnology in Q1 2024 and held it in 2 quarters.
Atom Investors's Vir Biotechnology position peaked at $190K in Q3 2025.
218 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.